Source: PharmiWeb

MolecularMD: MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®

MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Compani...

Read full article »
MolecularMD's Competitors | MolecularMD's News | MolecularMD's Financials
Stay up-to-date with the latest news on MolecularMD
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Dan Snyder's photo - President & CEO of MolecularMD

President & CEO

Dan Snyder

CEO Approval Rating

79/100

Read more
Stay up-to-date with the latest news on MolecularMD